In This Article:
(Bloomberg) -- Bayer AG is seeking shareholder authorization to raise billions of euros through a capital increase in case it needs to quickly resolve its US legal troubles, causing the stock price to plummet.
Most Read from Bloomberg
-
Trump Administration Plans to Eliminate Dozens of Housing Offices
-
NJ College to Merge With State School After Financial Stress
-
Republican Mayor Braces for Tariffs: ‘We Didn’t Budget for This’
-
NYC’s Finances Are Sinking With Gauge Falling to 11-Year Low
The German company will seek approval at its annual meeting next month for a potential equity offer of 35% of its current share capital, according to a letter from Supervisory Board Chairman Norbert Winkeljohann.
The proceeds would be used exclusively for strengthening the balance sheet during a resolution of the US litigation and not to finance mergers and acquisitions, Winkeljohann said. Bayer doesn’t currently have specific plans to act on the authorization, he added.
The German company’s shares dropped as much as 10% on the news, the most intraday since November. The stock has tumbled since the acquisition of Monsanto in 2018, bringing its current market valuation to about €23 billion ($25 billion). That deal brought Bayer products that soon became subject to mass litigation in the US, including the weedkiller Roundup and toxic PCBs.
Chief Executive Officer Bill Anderson is trying to revive the fortunes of crisis-rattled Bayer, which only a decade ago was Germany’s most valuable company. The American CEO has pushed through operational changes in the past year designed, among other things, to speed up decision making. The revamp has resulted in about 7,000 job cuts.
Yet Anderson has struggled to tackle some of Bayer’s major challenges — from high debt levels to a weak pharma pipeline — thanks in part to the litigation. Last year, he resisted pressure from some investors to split up its conglomerate business model, with its divisions focused on agriculture, pharmaceuticals and consumer health. He cited the legal woes as one reason, but didn’t rule out such structural changes in the future.
Bayer’s proposed capital increase is prudent and could raise €11 billion in additional funding, Jason Miner, an analyst at Bloomberg Intelligence, said in a note. Still, it sends a negative signal about the potential size of litigation costs, he said.
Bayer has already spent about $10 billion of the $16 billion it had set aside for the US lawsuits over Roundup, which plaintiffs allege caused their cancer and Bayer insists is safe. The company has also agreed to pay almost $2 billion to settle cases related to toxic PCBs brought by US states, cities and counties. More trials are looming on both fronts.